Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

436 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Involvement of BH3-only proteins in hematologic malignancies.
Kuroda J, Taniwaki M. Kuroda J, et al. Crit Rev Oncol Hematol. 2009 Aug;71(2):89-101. doi: 10.1016/j.critrevonc.2008.10.004. Epub 2008 Nov 20. Crit Rev Oncol Hematol. 2009. PMID: 19022681 Review.
c-myc overexpression is not mandatory in aggressive-phase multiple myeloma with Burkitt's type translocation.
Kuroda J, Kimura S, Akaogi T, Hayashi H, Nishida K, Taniwaki M, Kashima K, Abe T, Kobayashi Y, Kondo M. Kuroda J, et al. Ann Hematol. 2000 Sep;79(9):514-8. doi: 10.1007/s002770000160. Ann Hematol. 2000. PMID: 11043423
Aggressive natural killer cell leukemia/lymphoma: a comprehensive cytogenetic study by spectral karyotyping.
Kuroda J, Kimura S, Akaogi T, Hayashi H, Nishida K, Kakazu N, Abe T. Kuroda J, et al. Ann Hematol. 2000 Sep;79(9):519-22. doi: 10.1007/s002770000179. Ann Hematol. 2000. PMID: 11043424
Agranular CD4+CD56+ blastic natural killer leukemia/lymphoma.
Kimura S, Kakazu N, Kuroda J, Akaogi T, Hayashi H, Nishida K, Abe T. Kimura S, et al. Among authors: kuroda j. Ann Hematol. 2001 Apr;80(4):228-31. doi: 10.1007/s002770000257. Ann Hematol. 2001. PMID: 11401089
Antiproliferative efficacy of the third-generation bisphosphonate, zoledronic acid, combined with other anticancer drugs in leukemic cell lines.
Kimura S, Kuroda J, Segawa H, Sato K, Nogawa M, Yuasa T, Ottmann OG, Maekawa T. Kimura S, et al. Among authors: kuroda j. Int J Hematol. 2004 Jan;79(1):37-43. doi: 10.1007/BF02983531. Int J Hematol. 2004. PMID: 14979476
Efficacy of the third-generation bisphosphonate, zoledronic acid alone and combined with anti-cancer agents against small cell lung cancer cell lines.
Matsumoto S, Kimura S, Segawa H, Kuroda J, Yuasa T, Sato K, Nogawa M, Tanaka F, Maekawa T, Wada H. Matsumoto S, et al. Among authors: kuroda j. Lung Cancer. 2005 Jan;47(1):31-9. doi: 10.1016/j.lungcan.2004.06.003. Lung Cancer. 2005. PMID: 15603852
Intravesical administration of small interfering RNA targeting PLK-1 successfully prevents the growth of bladder cancer.
Nogawa M, Yuasa T, Kimura S, Tanaka M, Kuroda J, Sato K, Yokota A, Segawa H, Toda Y, Kageyama S, Yoshiki T, Okada Y, Maekawa T. Nogawa M, et al. Among authors: kuroda j. J Clin Invest. 2005 Apr;115(4):978-85. doi: 10.1172/JCI23043. Epub 2005 Mar 10. J Clin Invest. 2005. PMID: 15761500 Free PMC article.
Zoledronic acid mediates Ras-independent growth inhibition of prostate cancer cells.
Nogawa M, Yuasa T, Kimura S, Kuroda J, Segawa H, Sato K, Yokota A, Koizumi M, Maekawa T. Nogawa M, et al. Among authors: kuroda j. Oncol Res. 2005;15(1):1-9. doi: 10.3727/096504005775082093. Oncol Res. 2005. PMID: 15839301
Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic.
Kuroda J, Puthalakath H, Cragg MS, Kelly PN, Bouillet P, Huang DC, Kimura S, Ottmann OG, Druker BJ, Villunger A, Roberts AW, Strasser A. Kuroda J, et al. Proc Natl Acad Sci U S A. 2006 Oct 3;103(40):14907-12. doi: 10.1073/pnas.0606176103. Epub 2006 Sep 22. Proc Natl Acad Sci U S A. 2006. PMID: 16997913 Free PMC article.
Apoptosis-based dual molecular targeting by INNO-406, a second-generation Bcr-Abl inhibitor, and ABT-737, an inhibitor of antiapoptotic Bcl-2 proteins, against Bcr-Abl-positive leukemia.
Kuroda J, Kimura S, Strasser A, Andreeff M, O'Reilly LA, Ashihara E, Kamitsuji Y, Yokota A, Kawata E, Takeuchi M, Tanaka R, Tabe Y, Taniwaki M, Maekawa T. Kuroda J, et al. Cell Death Differ. 2007 Sep;14(9):1667-77. doi: 10.1038/sj.cdd.4402168. Epub 2007 May 18. Cell Death Differ. 2007. PMID: 17510658
436 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback